<DOC>
	<DOCNO>NCT00250601</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety saredutant ( SR48968C ) patient depression . The primary objective evaluate efficacy 100 mg dose saredutant compare placebo patient depression . The secondary objective evaluate safety saredutant , evaluate efficacy saredutant disability quality life patient depression , evaluate blood level saredutant .</brief_summary>
	<brief_title>An Eight-week Study Evaluate Efficacy Safety Saredutant Patients With Depression</brief_title>
	<detailed_description>The study multicenter , US , randomize , parallel-group , double blind , placebo paroxetine-controlled study consist three segment ( A , B , C ) . Segment A 1-week , placebo , single-blind period Segment B 8-week , double blind period . Patients complete Segment B may eligible enrollment Segment C , 44-week , double blind extension . All randomized patient must complete post-study telephone visit post-study office visit 3 day 1 week , respectively , intake last dose study medication .</detailed_description>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<criteria>1.Male female patient . 2.18 64 year age . 3 . Inpatients outpatient . 4 . Written informed consent patient and/or legally authorize representative . 5 . Able comply protocol follow write verbal instruction . 6 . Subjects childbearing potential must confirm negative serum bhCG test prior entry Segment B must employ acceptable method birth control ( e.g. , oral , depot , implant contraceptive method , IUDs , sterilization , barrier method conjunction spermicide ) . 7 . Diagnosis major depressive disorder , define Diagnostic Statistical Manual Mental Disorders , 4th edition , Text Revision criterion confirm semistructured Mini International Neuropsychiatric Interview ( MINI ) , recurrent episode least one month prior entry . 8 . Minimum total score 22 MontgomeryAsberg Depression Rating Scale ( MADRS ) . 1.Patients whose current depressive episode diagnose psychotic feature , catatonic feature , seasonal pattern postpartum onset . 2.The duration current depressive episode great 2 year . 3.Patients currently suicidal history suicide attempt within 3 year prior entry . 4.Patients whose current depressive episode secondary general medical disorder . 5.Patients history presence bipolar disorder psychotic disorder accord D L criterion MINI . 6.Patients alcohol dependence abuse substance dependence abuse past 12 month except nicotine caffeine dependence . 7.Patients history failure respond treatment paroxetine antidepressant medication . 8.Patients use follow prior entry Segment B : antipsychotic within 3 month , fluoxetine within 35 day , monoamine oxidase inhibitor within 21 day , antidepressant , anxiolytic , sedativehypnotic , moodstabilizer ( lithium , anticonvulsant ) within 7 day except permitted concomitant medication . 9.Females pregnant breastfeeding . 10.Severe unstable cardiovascular , renal , hepatic , respiratory , hematological , endocrinological , neurological , somatic disease might interfere evaluation study medication . 11.History seizure single childhood febrile seizure . 12.ECG abnormality potential clinical significance include QT interval Bazett 's correction 500 msec entry . 13.Use known inducer potent inhibitor CYP3A4 within 7 day entry . 14.Use drug know risk Torsade de Pointes within 7 day entry Segment B . 15.Participation clinical trial experimental therapy within 30 day prior entry prior participation clinical trial saredutant . 16.Patients positive HbsAg antiHCV antibody test screening . 17.Patients follow screening : ALT &gt; 2 time upper limit normal range ( XULN ) , AST &gt; 2XULN , GGT &gt; 3XULN , total conjugate bilirubin &gt; ULN .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>depression</keyword>
	<keyword>antidepressive agent</keyword>
	<keyword>control clinical trial</keyword>
</DOC>